

## Clinical & Translational Science Center Newsletter

July 2021

### Letter from the Director



Dear Colleagues,

Our CTSC staff have returned to campus and have hit the ground running with research operations moving forward at speed.

We have several impactful studies in the featured stories section this month. Our PCI group has completed enrollment for a study by Dr. Dustin which focuses on a novel method of pain relief for osteoarthritis of the knee. Osteoarthritis, which occurs when the cartilage that protects the ends of bones wears down over time, is the most common form of arthritis worldwide, affecting millions. In the US, osteoarthritis of the knee is one of the top causes of disability in older adults. Current therapies are limited to symptom management. Dr. Richter's study examines a method of relieving pain by harvesting and injecting adipose tissue into the knee. If efficacious, this method could replace or supplement the current symptom management methods.

The Biomedical Informatics group has begun collaborating with Dr. Christine Kasper of the UNM College of Nursing and LisaMarie Turk, a PhD candidate, in a pilot study examining the unique needs of adolescents and young adults with medical burdens and complex special health care needs. The team used data mining techniques on Cerner's National HealthFacts database to examine the different types of care transitions and were able to make accurate predictions about future care. This precision population health study provides information that can predict the effects of various policy interventions and enhance health equity and quality of care. The technique used will also be applicable for COVID-19, offering the possibility of predicting both the possible sequelae associated with COVID-19 infection for an individual, as well as predicting the pattern or patterns of care an individual might experience.

New Mexico will be reopening without COVID-19 pandemic restrictions on July 1, 2021. While this is a huge milestone, it does not mean the pandemic is over. We encourage you to sign up for vaccination if you have not already: <https://cvvaccine.nmhealth.org/>. Please explore the University's Bring Back the Pack COVID-19 guidance: <https://bringbackthepack.unm.edu>, as it provides important information to consider as we move through summer and into the fall semester.

All standard CTSC services are available. We encourage PIs to reach out to our Research Concierge ([HSC-CTSCResearchConcierge@salud.unm.edu](mailto:HSC-CTSCResearchConcierge@salud.unm.edu)) with questions and/or to setup a consultation with the CTSC team.

Every part of the CTSC is integral to our purpose and funding, and we aim to update each section of the CTSC newsletter monthly. Each PI has a personal, professional investment in the information we provide. Please submit that information to our team. The CTSC is here for your support.

If you are interested in a rigorous quantitative rural research project focused on COVID-19, please contact me ([RLarson@salud.unm.edu](mailto:RLarson@salud.unm.edu)) to start a dialogue. The committed faculty, staff, and students at CTSC continue their research projects and look for innovative ways to support our communities.

The Health Sciences Center Office of Research website contains information on specific research-related updates (including the Research Continuity Guidelines for both [Laboratories & Research Facilities](#) and [Clinical Trial Research Faculty & Staff](#)) and can be accessed through the following link: <https://hsc.unm.edu/research/>.

If you have any questions about our assets and services, please contact the CTSC Research Concierge at [HSC-CTSCResearchConcierge@salud.unm.edu](mailto:HSC-CTSCResearchConcierge@salud.unm.edu). If you have any issues finding the information that you need, please reach out to [the CTSC Newsletter Team](#) and they will get back to you.

Thanks so much for your continued support of the Clinical & Translational Science Center!

Warm regards,

Richard S. Larson, MD, PhD  
PI, CEO and Director, Clinical & Translational Science Center

## CTSC Leadership

**CTSC Director, CEO & Principal Investigator:** Richard S. Larson, MD, PhD

**Associate Director, CTSC:** Matthew Campen, PhD

**Associate Director, CTSC:** Nancy Pandhi, MD, PhD, MPH

**Chief Administrative Officer:** Carla Cordova, MPH

**Administrative Component Director:** Beth Tigges, PhD, RN, PNP, BC

**Tracking & Evaluation Module Lead:** Beth Tigges, PhD, RN, PNP, BC

**Quality & Efficiency Module Lead:** Beth Tigges, PhD, RN, PNP, BC

**Informatics Component Director:** Christophe Lambert, PhD

**Community & Collaboration Component Director:** Mark Unruh, MD

**Community Engagement Module Lead:** Nancy Pandhi, MD, PhD, MPH

**Collaboration and Commercialization Module Lead:** Eric Prossnitz, PhD

**Translational Endeavors (TE) Component Director:** Christopher Abbott, MD

**Translational Workforce Development (TWD) Module Lead:** Karlett Parra, PhD

**Pilot Translational & Clinical Studies (PTC) Module Lead:** Corey Ford, MD, PhD

**Research Methods (RM) Component Director:** Mark Unruh, MD

**Biostatistics, Epidemiology & Research Design (BERD) Module Lead:** Mark Unruh, MD

**Regulatory Knowledge & Support (RKS) Module Lead:** Corey Ford, MD, PhD

**Hub Research Capacity (HRC) Component Director:** Nancy Pandhi, MD, PhD, MPH

**Integration of Special Populations (ISP) Module Lead:** Nancy Pandhi, MD, PhD, MPH

**Participant Clinical Interactions (PCI) Director:** Christopher Abbott, MD  
**Network Capacity (NC) Component Director:** Hengameh Raissy, PharmD  
**Trial Innovation Network (TIN) Module Lead:** Hengameh Raissy, PharmD  
**Drug Discovery & Repurposing Core Lead:** Hakim Djaballah, PhD  
**Opioid-Use Populations with Integration, Outreach, Informatics, and Drug Discovery (OPIOIDD) Module Lead:** Kimberly Page, PhD, MPH  
**KL2 Mentored Career Development Component Director:** Matt Campen, PhD  
**Clinical Laboratory Medical Director:** Qian-Yun Zhang, MD, PhD

## Featured Stories

### ***PCI Completes Enrollment for Osteoarthritis Knee Pain Relief Study***

Dr. Dustin Richter, Assistant Professor in the Department of Orthopaedics and Rehabilitation, has enrolled his final participant into the trial: "Evaluating the efficacy of micro-fragmented adipose tissue and intra-articular corticosteroid injections for symptomatic knee osteoarthritis: a randomized, placebo-controlled study". The purpose of this study is to evaluate the possible benefits of Lipogems injection.

According to the Mayo Clinic website, osteoarthritis is the most common form of arthritis, affecting millions of people worldwide. It occurs when the protective cartilage that cushions the ends of the bones wears down over time. Knees are one of the most common joints affected by osteoarthritis. The symptoms include pain, stiffness, tenderness, loss of flexibility, grating sensation, bone spurs and swelling. Osteoarthritis of the knee affects about 15 million adults in the US and is one of the top causes of disability in older people, it is more common in women and obese persons.

While current therapies are limited to symptom management and are not capable of stopping the disease. Dr. Richter's study is the first study to examine the efficacy of Lipogems for pain relief of osteoarthritis in the knee in a randomized clinical trial. Lipogems is a "technique to harvest, process, and inject minimally manipulated adipose tissue. This procedure is enzyme free and requires no clonal expansion or manipulation. Lipoaspirate is harvested and washed in saline solution, then processed through a closed-system device that microfragments the adipose tissue. This mechanical process retains the vascular architecture, mature pericytes, and MSCs for autologous injection."

The study will be following up research participants for the next year, and then begin to evaluate their data with respect to the possible reduction in joint pain and increased joint functionality following injection of Lipogems. The PCI coordinator team has worked closely with Dr. Richter to support this trial, with the PCI research nurse receiving specialized training in Lipogems injections.

If you have questions about PCI services, please contact Donna Sedillo at [dlsedillo@salud.unm.edu](mailto:dlsedillo@salud.unm.edu)

### ***Informatics Collaborating to Study Adolescent Care Transitions into Adulthood***

The CTSC Biomedical Informatics group has been collaborating with Dr. Christine E. Kasper, PhD, RN, FAAN, FACS, Dean and Professor at the UNM College of Nursing and LisaMarie Turk, MSN, RN, PhD Candidate in abstracting data and supporting data mining, feature engineering, and programming for their CTSC pilot study entitled "De-identified Health Facts in Machine Learning and System Dynamics Modeling for Health Care Transition Study." The study focuses on the population of Adolescents and Emerging Adults with medical burdens and complex special health care needs during transition to adulthood. Using Cerner's National HealthFacts database, the researchers found the

different types of transition using cluster analysis and were able to predict future acute care visits and disease severity using a time-series neural network. The trained network is then used to make predictions about the effects of various policy interventions and enhance understanding of the health services system in the context of health care transition for the study population.

This precision population health study provides information that support agendas of health equity, quality in care, health policy, and clinical decision support. Of particular novel concern, is predictive methodology for COVID-19. This approach also offers a predictive methodology for COVID-19, for example to identify phenotypes that would allow us to predict, based on a person's background, how likely they are to undergo one or another pattern of health services system service utilization and sequelae associated with COVID-19 infection.

## Menu of Services & Resources

- [Biostatistics Support](#)
- [Brain & Behavioral Disorders](#)
- [Citing the Clinical & Translational Science Center](#)
- [Clinical Trials Participant Clinical Interactions](#)
- [Community Engagement](#)
- [Community Health Network](#)
- [Database Mining](#)
- [Drug Repurposing](#)
- [KL2 Scholars](#)
- [Intramural Funding](#)
- [Laboratory Services](#)
- [Pilot Funding](#)
- [Trial Innovation Network](#)
- [Quality & Efficiency](#)
- [Regulatory Knowledge & Support](#)
- [Rural Health Research](#)
- [Team Science & Commercialization](#)
- [Training](#)
- [Vulnerable Populations](#)

## Administration

### Tracking & Evaluation (T&E)

The Tracking and Evaluation Team is piloting a new "Common Metric" called the Median Accrual Metric. This metric is intended to look at our CTSC's ability to recruit and retain research participants. This metric will look at the entire calendar year for 2020 and will be reported in August of 2021.

### Quality & Efficiency (Q&E)

The Quality and Efficiency Team continues to work on two specific process improvements initiatives. These two projects will conclude in June of 2021 and will be evaluated for how the projects impacted our CTSC.

## Community & Collaboration (C&C)

### Community Engagement & Research Core (CERC)

#### **Qualitative Research Office Hours**

The CTSC Qualitative Research Network is a place for qualitative researchers at all levels to connect and learn and includes quarterly meetings, office hours, and more. Details are below. Let the CTSC know if you'd like to join, and we'll add you to our distribution list and meeting invites. Please also let us know if you're interested in being added to the invite for office hours.

*If you're interested, please complete this [quick survey](#) (~1 minute) about yourself.*

- **Quarterly Meetings:** Each meeting offers opportunities for networking and covers a main topic discussion or presentation. Example meeting topics: Conducting Qualitative Research from a Distance in our New COVID World, Using NVivo for Lit Reviews, Using NVivo with Research Teams, and Bringing Patient Voices to American Health Care with DIPEX Methodology and the Health Experience Research Network (HERN).
- **Qualitative Research Office Hours:** Once a month the QRN holds office hours. At these meetings, you are welcome to bring any questions related to qualitative research. For the first 30 minutes, we will cover one of the topics below (subject to change); the second 30 minutes are open to discuss anything you'd like related to qualitative research.
  - Basics of coding
  - Basics of NVivo coding
  - Running reports in NVivo
  - Basics of interviewing
  - Basics of focus group facilitation
- **Resources:** Please follow this [link](#) to find various resources related to qualitative research. These include training resources and best practices related to qualitative data software, collection, remote research/research during a pandemic, as well as opportunities (e.g., funding and conferences). Please email me with any additional resources you think would be helpful for this site.
- **Network Contacts:** If you're interested in having your contact information and research interests/expertise shared with the group, please include this in your survey responses (above).

### Team Science & Commercialization

CTSC promotes several events a year to promote Team Science and Commercialization- including both Hackathon and BioVenture. Promoting collaboration across academic disciplines, scientists can bring together ideas and fill in gaps to help move research out of the lab and into the market.

These events bring together clinicians, engineers, entrepreneurs, programmers, scientists, and students to form teams that worked to develop healthcare innovations and design a pitch allowed participants to practice skills necessary to begin the process of commercialization, a vital step to ensure technologies can reach patients.

For additional information and to register for upcoming Synergy meetings, please visit the webpage: <https://hsc.unm.edu/research/ctsc/programs/team-science.html>.

Find out more about ASCEND Hub resources and activities on the ASCEND Hub website: <https://ascendhub.org>.

## Translational Endeavors (TE)i

## Translational Workforce Development (TWD)

Translational Workforce Development has numerous [course offerings](#) and can even provide consultations as requested to assist you in your goals! Please request a [consultation](#) or additional information on any courses offered. The TWD team may be reached via [HSC-CTSC Training@salud.unm.edu](mailto:HSC-CTSC Training@salud.unm.edu).

For information regarding TWD, please visit our webpage: <https://hsc.unm.edu/research/ctsc/training/index.html>.

## Pilot Awards

The UNM CTSC provides a variety of Pilot Award Programs that distribute intramural funding for clinical and translational research at the Health Sciences Center, including two rounds of funding for our standard RFAs annually. To access a Funding Calendar of CTSC opportunities, please use this link:

<https://hsc.unm.edu/research/ctsc/pilot-funding/funding-calendars/index.html>.

Please visit our web site at <https://hsc.unm.edu/research/ctsc/pilot-funding/index.html> for additional information.

## Research Methods (RM)

### Biostatistics, Epidemiology, and Research Design (BERD)

#### **Biostatistics Consultation Services Available at CTSC**

The Biostatistics, Epidemiology, and Research Design (BERD) Core provides consultation and services, novel tools and methods intended to solve problems, and address barriers to the conduct of clinical and translational research. Services are open to all Health Sciences investigators (staff, students, and faculty) to understand the methodological aspects of their research for planning their projects, including power analysis, sample size, and research design for intermural and extramural grant submissions.

If you have a current pilot study that requires biostatistical support, please schedule appointments as soon as possible.

Are you interested in applying for a pilot study? It is strongly recommended that you make an appointment with one of our biostatisticians prior to your submission. Our expert biostatisticians can help in the initial stages of project development.

Appointments are available; but do fill up quickly. To schedule an appointment, please contact [HSC-CTSCbiostats@salud.unm.edu](mailto:HSC-CTSCbiostats@salud.unm.edu). Services are offered Monday through Friday.

Please visit our web site: <http://hsc.unm.edu/research/ctsc/biostatistics/index.html>.

### Regulatory Knowledge & Support (RKS)

The University of New Mexico in collaboration with the Western Institutional Review Board (WIRB), allows CTSC Investigators will be able to streamline study start up activities for new clinical trials through the Clinical Research and Regulatory Support Services well as initiate studies in a prompt and efficient manner. WIRB has been at the forefront of protecting the rights and welfare of human subjects. They provide in-depth regulatory expertise to support the development of research protocols and documentation.

WIRB is an independent IRB that has maintained full accreditation from the Association for the Accreditation of Human Research Protection Programs (AAHRPP) since 2003. If you are interested in exploring the possibility of using WIRB in conjunction with our Regulatory Management and/or Study Coordinator services, please complete the

Request for Resources Form and submit to CTSC Research Concierge at [HSC-CTSCResearchConcierge@salud.unm.edu](mailto:HSC-CTSCResearchConcierge@salud.unm.edu).

To qualify for this service, you must obtain Departmental Review and Approval, provide a fully industry sponsored Phase II, III, or IV clinical trial, and utilize our CTSC Regulatory Support Service in addition to other CTSC Resources.

For more information, please contact Rebecca Brito at [rbrito@salud.unm.edu](mailto:rbrito@salud.unm.edu)

## Hub Research Capacity (HRC)

### Integrating Special Populations (ISP)

The aim of the CTSC ISP team is to identify, develop, and deploy strategies to involve populations who are underserved or otherwise underrepresented in all stages of research. Urging investigators to design scientifically sound CTR that includes special populations from the outset is of critical importance. To aid investigators in these efforts, ISP has developed the new specialized Rurally Engaged, Spanish speaking or Network Specialized Experts (RESPONSE) team led by experienced faculty with mixed-methods CTR expertise. This group will provide pre-proposal consultations. Consultations will focus on best practices and considerations in New Mexico's special populations, and identify and connect investigators to potential engagement partners, collaborators, and UNM CTSC resources and services. The team coordinates closely with other CTSC cores (e.g., CERC, Translational Endeavors, KL2). Consults are currently available via web-based technology.

If you would like to request a consultation, please fill out the intake form at the following link.

<https://ctsctrials.health.unm.edu/redcap/surveys/?s=NNH84CWCAK>

For more information, please contact Jesus Fuentes at [JEFuentes@salud.unm.edu](mailto:JEFuentes@salud.unm.edu)

For more information about the Integrated Special Population team, please contact Dr. Nancy Pandhi, MD, PhD, MPH at [NPandhi@salud.unm.edu](mailto:NPandhi@salud.unm.edu).

For more information on Integrating Special Populations, please use the following link:


<https://hsc.unm.edu/research/ctsc/Community-Engaged-Research-Core/integrating-special-populations.html>

### Community Health Network (CHN)

In May 2021, Cynthia Killough, MA, the Community Health Manager and Community Health Specialist with the CTSC presented at the New Mexico Public Health Association 2021 Virtual Conference. Her presentation titled *Lessons Learned from Engaging Communities in Health Research during COVID-19* provided tips and recommendations based on her experiences as a community liaison as well as community engaged literature. In her presentation, Cynthia reminded the audience that in health research it is important that diverse and under-represented communities have a voice so that study findings can be generalized to the public and patients can benefit faster to achieve their health goals. Before the pandemic, challenges to community engagement in health research comprised the lack of inclusion from diverse populations, stigma associated with research and grievances with past research projects to name a few. During the pandemic access to the internet and computers added to the list of pre-existing challenges. Despite these barriers, Cynthia was able to promote study opportunities to rural communities across the state and continued to build relationships with individuals. Some of the tips Cynthia shared were the following: 1.) Attend meetings regularly, 2.) Involve the community early in your work, 3.) Connect communities to



others/experts/resources, 4.) Get your hands dirty- volunteer, 5.) Disseminate study results back to communities (see Figure 1).



**Figure 1.** Example of data dissemination from CHN/CHS power point presentation to community health councils during the COVID-19 pandemic. Data came from Dr. Julie Salvador’s Medication Assisted Treatment (MAT) ECHO-F study for patients with Opioid Use Disorder (OUD), which supports rural, primary care providers and staff in NM and bordering areas by providing ECHO sessions and facilitation so they can successfully start or expand MAT to help OUD patients.

Cynthia had such a fun time presenting to the NMPHA and got really great feedback and interest about how to be more community-based in research practices in the weeks after the conference. Her hope is that together we can break down stigma associated with research and get study results out faster to patients so that they can achieve their health goals.

## Network Capacity (NC)

### Trial Innovation Network (TIN)

The Trial Innovation Network is a collaborative initiative within the CTSA Program and is composed of three key partners: the CTSA Program Hubs, the Trial Innovation Centers (TICs), and the Recruitment Innovation Center (RIC).

The vision for the Trial Innovation Network is to innovatively address critical roadblocks in clinical research and accelerate the translation of novel interventions into life-saving therapies.

The Trial Innovation Network is a collaborative national network with a focus in three main areas: operational innovation, operational excellence, and collaboration. The Trial Innovation Network will leverage the expertise and resources of the CTSA Program. The Trial Innovation Network will feature a single IRB system, master contracting agreements, quality by design approaches, and a focus on evidence-based strategies to recruitment and patient engagement.

The goal of the Trial Innovation Network is to not only execute trials better, faster, and more cost-efficiently but, importantly, to be a national laboratory to study, understand and innovate the process of conducting clinical trials.



The University of New Mexico CTSC has been a part of the Trial Innovation Network and as a result has been a participating site in several studies that impact a variety of disease states. This important work has helped connect physicians at the University of New Mexico with the clinical trials specific to their specialty. This effort has encouraged new investigators to become engaged in clinical research. This collaboration is part of the larger mission to move innovated research from the bench, to the bedside, and ultimately out into the communities in which we live.

For more information on the Trial Innovation Network, please contact George Garcia at [gemgarcia@salud.unm.edu](mailto:gemgarcia@salud.unm.edu).

## Drug Discovery & Repurposing Core (DDRC)

### ***The DDRC is a Resource for Rapidly Translating Existing Drugs into New Clinical Trials***

Do you have ideas about ways to repurpose existing FDA-approved drugs? The CTSC is here to help. Dr. Hakim Djaballah, Module Lead for the Clinical & Translational Science Center Drug Discovery and Repurposing Core (DDRC) collaborates with UNM investigators other CTSCs to improve health outcomes by providing unique resources for rapidly translating existing drugs for use in new clinical trials. DDRC provides access to and operation of state-of-the-art technology in drug rescue, repurposing, and repositioning through innovative tools that support investigators and start-up companies. Additionally, DDRC provides support and guidance in translating pilot projects from preclinical proof-of-principle to clinical proof-of-concept as well as helps to develop first-in-human clinical trials.

For additional information or to become a DDRC member, please visit the DDRC (formerly DR3N) webpage: <https://hsc.unm.edu/research/ctsc/dr3n/index.html>.

## Opioid-Use Populations with Integration, Outreach, Informatics, and Drug Discovery (OPIOIDD)

Please stay tuned for upcoming announcements about the work of Kimberly Page PhD, MPH, and her team, in conjunction with New Mexico communities and the CTSC cores.

The new NCATS study “Collaborative care teams for hospitalized patients with opioid use disorders: Translating evidence into practice” will be supported at UNM by Kimberly Page ([pagek@salud.unm.edu](mailto:pagek@salud.unm.edu)), other faculty, and Dr. Page’s team.

If you would like more information on this vital effort, please contact Dr. Page at [pagek@salud.unm.edu](mailto:pagek@salud.unm.edu).

## Clinical Laboratory (T-Laboratory)

### ***CTSC Lab Installs New PCR System***

The CTSC’s translational lab has a new instrument for studying gene expression. The new QuantStudio 7 Flex PCR (Polymerase Chain Reaction) system allows investigators using the CTSC lab to detect changes in gene expression as low as 1.5-fold. The instrument supports a wide range of genomic applications, such as analyses of gene expression, microRNAs and noncoding RNAs, copy number variation, drug metabolism enzymes, and protein expression; SNP genotyping; and mutation detection.

The QuantStudio 7 Flex was selected in part for its versatility. Investigators can now easily interchange between 96-well and 384-well format, and it can run a TaqMan Array card (a 384-well card that enables the loading of 384 targets with 8 pipetting steps in less than 10 minutes). It is automation compatible, and its intuitive software will enable quick and easy procedures.

### **Using CTSC Lab Services**

The CTSC Translational Laboratory (T-Laboratory) is comprised of 6,000 square feet of wet-lab space, located in the newly renovated CTSC Building. The T-Laboratory offers state-of-the-art equipment and technical assistance with laboratory techniques for UNM HS investigators. The experienced staff of the T-Laboratory provide specialized laboratory support, customized to meet the needs of the investigators in all aspects of research including protocol/assay development, budget preparation, and testing of patient samples for various assays. The T-Laboratory provides sample preparation and technical support for other non-CTSC resources such as UNM Shared Flow Cytometry and High Throughput Screening Resource, and KUSAIR Small Animal Imaging. In addition, our staff will provide training to UNM HS investigators staff on molecular techniques, clinical techniques, or equipment. There are three options for utilization of CTSC T-Laboratory Services:

- Option A: Full Service Sample Testing
- Option B: Equipment Utilization by Investigator
- Option C: Preparation of Investigator’s Experiments or Train Investigator’s Staff to Perform Assays and Equipment.

Additionally, the CTSC Clinical Laboratory develops and carries out research-related sample analyses for UNM HS investigators, researchers throughout the United States and world, as well as corporate funded research projects.

For questions, please contact [HSC-CTSCResearchConcierge@salud.unm.edu](mailto:HSC-CTSCResearchConcierge@salud.unm.edu).

### **Funding Opportunities Specific to COVID-19**

There are several significant funding opportunities available through the CTSC to address the COVID-19 pandemic. CTSC monitors these opportunities for our HSC faculty on a weekly basis and includes additional information from the NIH COVID-19 funding site for your convenience.

Some of these funding opportunities require an active grant or cooperative agreement. They may also need a Letter of Support from Dr. Larson, the CTSC PI. Please contact Michelle Parra ([MMParra@salud.unm.edu](mailto:MMParra@salud.unm.edu)) if you are interested in applying for any of the COVID-19 funding opportunities listed below.

**Recent Active Funding Opportunities Specific to COVID-19 are listed below:**

Title	Notice Number	Organization(s)	Release Date	RFA/PA/ PAR #	Expiration Date	Activity Code(s)
Notice of Special Interest (NOSI) Announcing the Availability of	<a href="#">NOT-DA-21-041</a>	<a href="#">NIDA</a>	Apr 15, 2021	<a href="#">PA-20-272</a> <a href="#">PA-18-935</a> (Urgent Supplement)	Mar 31, 2022	333

<b>Administrative Supplements and Urgent Competitive Revisions for Research on the 2019 Novel Coronavirus</b>						
<b>Emergency Awards: Community-engaged COVID-19 Testing Interventions among Underserved and Vulnerable Populations RADx-UP Phase II (U01 Clinical Trial Optional)</b>	<a href="#">RFA-OD-21-008</a>	<a href="#">NIH</a> , <a href="#">NIBIB</a> , <a href="#">NIDDK</a> , <a href="#">NIEHS</a> , <a href="#">NIMH</a> , <a href="#">NINDS</a> , <a href="#">NINR</a> , <a href="#">NIA</a> , <a href="#">NIAAA</a> , <a href="#">NIDCD</a> , <a href="#">NIDA</a> , <a href="#">NIMHD</a> , <a href="#">NLM</a> , <a href="#">OBSSR</a> , <a href="#">ODP</a> , <a href="#">SGMRO</a> , <a href="#">THRO</a> , <a href="#">NIDCR</a> , <a href="#">NHLBI</a> , <a href="#">ECHO</a> , <a href="#">NICHD</a> , <a href="#">NCI</a> , <a href="#">NCATS</a> , <a href="#">NCCIH</a> , <a href="#">NEI</a> , <a href="#">NHGRI</a> , <a href="#">NIAID</a> , <a href="#">NIAMS</a> , <a href="#">NIGMS</a> , <a href="#">ORWH</a>	Apr 13, 2021	<a href="#">RFA-OD-21-009</a> , <a href="#">U01</a> Research Project (Cooperative Agreements) <a href="#">NOT-OD-21-103</a> <a href="#">NOT-OD-21-101</a>	Jul 8, 2021	U01
<b>Notice of Special Interest (NOSI): Availability of Emergency Competitive Revisions for the Clinical and Translational Science Award (CTSA) Program to Address COVID-19 Public Health Needs</b>	<a href="#">NOT-TR-21-022</a>	<a href="#">NCATS</a>	Feb 26, 2021	<a href="#">PA-20-135</a>	Aug 17, 2021	333
<b>Notice of Special Interest (NOSI): Availability of Urgent Competitive Revisions for Modeling Research on Coronavirus</b>	<a href="#">NOT-GM-21-019</a>	<a href="#">NIGMS</a>	Feb 25, 2021	<a href="#">PA-18-935</a>	Dec 16, 2021	333

<b>Disease 2019 (COVID-19) and the Causative Virus SARS-CoV-2</b>						
<b>Notice of Special Interest (NOSI): Telehealth Strategies for Individuals with HIV and Substance Use Disorders</b>	<a href="#">NOT-DA-21-019</a>	<a href="#">NIDA</a>	Feb 10, 2021	<a href="#">PA-20-184</a> <a href="#">PA-20-183</a> <a href="#">PA-20-200</a> <a href="#">PA-20-195</a> <a href="#">PA-20-194</a> <a href="#">PA-20-196</a> <a href="#">PA-20-146</a>	Sep 8, 2024	R01, R03, R21
<b>Notice of Special Interest (NOSI): Medical Consequences of Smoking and Vaping Drugs of Abuse in Individuals with HIV and COVID-19</b>	<a href="#">NOT-DA-21-017</a>	<a href="#">NIDA</a>	Feb 4, 2021	<a href="#">PA-20-184</a> <a href="#">PA-20-183</a> <a href="#">PA-20-200</a> <a href="#">PA-20-195</a> <a href="#">PA-20-194</a> <a href="#">PA-20-196</a>	Sep 8, 2024	R01, R02, R03
<b>Notice of Special Interest (NOSI): Complement in Basic Immunology (CIBI)</b>	<a href="#">NOT-AI-21-008</a>	<a href="#">NIAID</a>	Feb 4, 2021	<a href="#">PA-20-185</a> <a href="#">PA-20-195</a>	Jan 8, 2023	R01, R21
<b>Notice of Special Interest (NOSI): Long-Term Neurocognitive Consequences of COVID-19 in Individuals Living with HIV and Substance Use Disorders</b>	<a href="#">NOT-DA-21-018</a>	<a href="#">NIDA</a>	Feb 3, 2021	<a href="#">PA-20-184</a> <a href="#">PA-20-183</a> <a href="#">PA-20-200</a> <a href="#">PA-20-195</a> <a href="#">PA-20-194</a> <a href="#">PA-20-196</a> <a href="#">PA-20-146</a>	Sep 8, 2024	R01, R03, R21
<b>Notice of Special Interest (NOSI):</b>	<a href="#">NOT-TR-21-017</a>	<a href="#">NCATS</a>	Feb 3, 2021	<a href="#">PA-20-272</a>	Aug 17, 2024	333

<b>Administrative Supplements for the Clinical and Translational Science Award (CTSA) Program to Address COVID-19 Public Health Needs</b>						
<b>Notice of Special Interest (NOSI): NIDCR Support for Research on the Physiological Involvement of Oral Cavity in Coronavirus Disease 2019 (COVID-19)</b>	<a href="#">NOT-DE-21-001</a>	<a href="#">NIDCR</a>	Jan 26, 2021	<a href="#">PA-20-185</a> <a href="#">PA-20-195</a>	May 28, 2023	R01, R21
<b>Notice of Special Interest (NOSI): Aging-Relevant Behavioral and Social Research on Coronavirus Disease 2019 (COVID-19)</b>	<a href="#">NOT-AG-21-015</a>	<a href="#">NIA</a>	Jan 26, 2021	<a href="#">PA-20-183</a> <a href="#">PA-20-184</a> <a href="#">PA-20-185</a> <a href="#">PA-20-200</a> <a href="#">PA-20-194</a> <a href="#">PA-20-196</a> <a href="#">PA-20-195</a> <a href="#">PAR-19-374</a> <a href="#">PAR-19-314</a> <a href="#">PAR-19-070</a> <a href="#">PAR-19-071</a> <a href="#">PAR-20-070</a>	May 28, 2023	R01, R03, R21, U19, P01, R21/R33
<b>Notice of Special Interest (NOSI): Effects of smoking and vaping on the risk and outcome of COVID-19 infection</b>	<a href="#">NOT-DA-21-011</a>	<a href="#">NIDA</a>	Jan 26, 2021	<a href="#">PA-20-184</a> <a href="#">PA-20-183</a> <a href="#">PA-20-200</a> <a href="#">PA-20-195</a> <a href="#">PA-20-194</a> <a href="#">PA-20-196</a> <a href="#">PA-20-146</a>	Sep 8, 2024	R01, R03, R21
<b>Notice of Special Interest: Promoting Research on</b>	<a href="#">NOT-AR-21-012</a>	<a href="#">NIAMS</a>	Jan 5, 2021	<a href="#">PA-20-185</a> <a href="#">PA-20-195</a> <a href="#">PAR-21-055</a> <a href="#">PAR-21-054</a>	Nov 19, 2021	R01, R02

COVID-19 and Rheumatic, Musculoskeletal and Skin Diseases				<a href="#">PAR-21-053</a>		
Notice of Special Interest: Administrative Supplements for COVID-19 Impacted NIMH Research	<a href="#">NOT-MH-21-120</a>	<a href="#">NIMH</a>	Dec 23, 2020	<a href="#">PA-20-272</a>	Jun 2, 2023	333
Notice of Special Interest (NOSI): Research to Address Vaccine Hesitancy, Uptake, and Implementation among Populations that Experience Health Disparities	<a href="#">NOT-MD-21-008</a>	<a href="#">NIMHD</a> , <a href="#">NIAID</a> , <a href="#">NIAMS</a> , <a href="#">NCI</a> , <a href="#">ORWH</a> , <a href="#">NIMH</a> , <a href="#">NINR</a> , <a href="#">OBSSR</a> , <a href="#">ODP</a> , <a href="#">NHLBI</a> , <a href="#">NIDCR</a> , <a href="#">SGMRO</a>	Dec 17, 2020	<a href="#">PA-20-183</a> <a href="#">PA-20-185</a>	Jan 8, 2022	R01
Notice of Special Interest (NOSI): Effects of smoking and vaping on the risk and outcome of COVID-19 infection	<a href="#">NOT-DA-20-084</a>	<a href="#">NIDA</a>	Oct 27, 2020	<a href="#">PA-20-183</a> <a href="#">PA-20-200</a> <a href="#">PA-20-195</a>	Sep 8, 2024	R01, R03, R21
Mobile Health Solutions to rectify digital inequality in communities affected by drug addiction (R43/R44 Clinical Trial Optional)	<a href="#">RFA-DA-22-001</a>	<a href="#">NIDA</a>	Apr 27, 2021	<a href="#">R43/R44</a>	Aug 14, 2021	R43/R44



<p><b>Notice of Special Interest (NOSI): Availability of Emergency Awards for Limited Clinical Trials to Evaluate Therapeutic and Vaccine Candidates Against SARS-CoV-2</b></p>	<p><a href="#">NOT-AI-20-065</a></p>	<p><a href="#">NIAID</a></p>	<p>Aug 13, 2020</p>	<p><a href="#">PAR-18-633</a></p>	<p>Sep 1, 2021</p>	<p>U01</p>
<p><b>Notice of Special Interest (NOSI): Simulation Modeling and Systems Science to Address Health Disparities</b></p>	<p><a href="#">NOT-MD-20-025</a></p>	<p><a href="#">NIMHD</a>, <a href="#">NCI</a>, <a href="#">NIDA</a>, <a href="#">NLM</a>, <a href="#">ODP</a>, <a href="#">OBSSR</a>, <a href="#">NIMH</a>, <a href="#">NIAMS</a></p>	<p>Aug 13, 2020</p>	<p><a href="#">PA-20-185</a></p>	<p>May 8, 2023</p>	<p>R01</p>
<p><b>Limited Competition Emergency Awards: Shared Personal Protective Equipment Resources for COVID-19 Related Vaccine and Treatment Clinical Trials and Clinical Studies (\$10 Clinical Trial Not Allowed)</b></p>	<p><a href="#">PAR-20-256</a></p>	<p><a href="#">NIAID</a></p>	<p>Jul 13, 2020</p>	<p><a href="#">PAR-20-256</a></p>	<p>Jul 8, 2021</p>	<p>S10</p>
<p><b>Notice of Special Interest (NOSI) regarding the Availability of Emergency</b></p>	<p><a href="#">NOT-AI-20-059</a></p>	<p><a href="#">NIAID</a></p>	<p>Jul 6, 2020</p>	<p><a href="#">PA-20-135</a></p>	<p>Jul 2, 2021</p>	<p>333</p>

<p><b>Competitive Revisions for Select Research Activities related to Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19)</b></p>						
<p><b>Notice of Special Interest (NOSI) regarding the Availability of Urgent Competitive Revisions and Administrative Supplements for Research on Coronavirus Disease 2019 (COVID-19) in Individuals with Down Syndrome for the INCLUDE Project</b></p>	<p><a href="#">NOT-OD-20-129</a></p>	<p><a href="#">NIH</a>, <a href="#">NCI</a>, <a href="#">NHGRI</a>, <a href="#">NCCIH</a>, <a href="#">NINDS</a>, <a href="#">ORIP</a>, <a href="#">NIMHD</a>, <a href="#">NIA</a>, <a href="#">NIDCR</a>, <a href="#">NIAID</a>, <a href="#">NIAMS</a>, <a href="#">NIEHS</a>, <a href="#">NCATS</a>, <a href="#">NIDCD</a>, <a href="#">NICHD</a>, <a href="#">NIDDK</a>, <a href="#">NHLBI</a></p>	<p>Jun 25, 2020</p>	<p><a href="#">PA-18-591</a> (Parent Admin Supplement) <a href="#">PA-18-935</a> (Urgent Supplement)</p>	<p>Jul 13, 2021</p>	<p>333</p>
<p><b>Notice of Special Interest (NOSI): NIDCD is Interested in Supporting Research on the Impact of COVID-19 on Mission Specific Sensory and Communication Disorders</b></p>	<p><a href="#">NOT-DC-20-008</a></p>	<p><a href="#">NIDCD</a></p>	<p>Jun 4, 2020</p>	<p><a href="#">PA-18-334</a> <a href="#">PA-20-185</a> <a href="#">PA-20-184</a> <a href="#">PA-20-196</a> <a href="#">PA-20-195</a> <a href="#">PA-19-270</a> <a href="#">PA-19-271</a> <a href="#">PA-19-273</a> <a href="#">PA-19-272</a></p>	<p>Sep 8, 2022</p>	<p>R01, R21, R41/R42, R43/R44</p>

<p><b>Notice of Special Interest (NOSI) regarding the Availability of Emergency Competitive Revisions to Existing NIH Grants and Cooperative Agreements for Tissue Chips Research on the 2019 Novel Coronavirus</b></p>	<p><a href="#">NOT-TR-20-017</a></p>	<p><a href="#">NCATS</a></p>	<p>Apr 9, 2020</p>	<p><a href="#">PA-20-135</a></p>	<p>Jan 26, 2022</p>	<p>333</p>
<p><b>Notice of Special Interest (NOSI) regarding the Availability of Administrative Supplements for Tissue Chips Research on the 2019 Novel Coronavirus</b></p>	<p><a href="#">NOT-TR-20-016</a></p>	<p><a href="#">NCATS</a></p>	<p>Apr 9, 2020</p>	<p><a href="#">PA-18-591</a></p>	<p>Jan 26, 2022</p>	<p>333</p>
<p><b>Notice of Special Interest (NOSI): Clinical and Translational Science Award (CTSA) Program Applications to Address 2019 Novel Coronavirus (COVID-19) Public Health Need</b></p>	<p><a href="#">NOT-TR-20-011</a></p>	<p><a href="#">NCATS</a></p>	<p>Mar 24, 2020</p>	<p><a href="#">PA-18-591</a> (Parent Admin Supplement) <a href="#">PA-18-935</a> (Urgent Supplement)</p>	<p>Jul 10, 2021</p>	<p>333, U01, R21, U54</p>
<p><b>Emergency Competitive Revision to Existing NIH</b></p>	<p><a href="#">PA-20-135</a></p>	<p><a href="#">NIH</a>, <a href="#">NCATS</a>, <a href="#">NCCIH</a>, <a href="#">NCI</a>, <a href="#">NHGRI</a>, <a href="#">NIA</a>, <a href="#">NIAAA</a>, <a href="#">NIAID</a>, <a href="#">NIAMS</a>, <a href="#">NIBIB</a>, <a href="#">NICHD</a>, <a href="#">NIDCD</a>,</p>	<p>Mar 10, 2020</p>	<p><a href="#">PA-20-135</a></p>	<p>Sep 8, 2025</p>	<p>333</p>

<b>Awards (Emergency Supplement - Clinical Trial Optional)</b>		<a href="#">NIDDK</a> , <a href="#">NIEHS</a> , <a href="#">NIGMS</a> , <a href="#">NIMH</a> , <a href="#">NIMHD</a> , <a href="#">NINR</a> , <a href="#">NLM</a> , <a href="#">ORWH</a> , <a href="#">OSC</a>				
<b>The Intersection of Sex and Gender Influences on Health and Disease (R01 Clinical Trial Optional)</b>	<a href="#">RFA-OD-19-029</a>	<a href="#">ORWH</a> , <a href="#">NCCIH</a> , <a href="#">NHGRI</a> , <a href="#">NHLBI</a> , <a href="#">NIA</a> , <a href="#">NIAAA</a> , <a href="#">NIAID</a> , <a href="#">NIDA</a> , <a href="#">NIDCR</a> , <a href="#">NIEHS</a> , <a href="#">NIMH</a> , <a href="#">NINR</a>	Sep 27, 2019	<a href="#">PA-20-272</a>	Nov 27, 2021	R01
<b>Emergency Award: Social, Behavioral, and Economic Research on COVID-19 Consortium (U01 Clinical Trial Not Allowed)</b>	<a href="#">PAR-21-213</a>	<a href="#">NIA</a> , <a href="#">NIDA</a> , <a href="#">ORWH</a> , <a href="#">NIMH</a> , <a href="#">NIAA</a> , <a href="#">NIMHD</a> , <a href="#">OBSSR</a> , <a href="#">NEI</a>	April 6, 2021	<a href="#">U01</a> Research Project (Cooperative Agreements)	Nov 9, 2021	U01
<b>Notice of Special Interest (NOSI): Administrative Supplements to NIMHD Awards for Research on HIV/AIDS in Populations that Experience Health Disparities (Admin Supp Clinical Trial Optional)</b>	<a href="#">NOT-MD-21-020</a>	<a href="#">NIMHD</a>	May 27, 2021	<a href="#">PA-20-272</a>	Jul 16, 2021	333

If you are interested in applying for any of the grants, please email Michelle Parra ([MMParra@salud.unm.edu](mailto:MMParra@salud.unm.edu)).

For a full listing of COVID-19 through NIH, please access the following site:

<https://grants.nih.gov/grants/guide/COVID-Related.cfm>.

**Citing the CTSC**

When citing the CTSC, please be sure to include our Grant numbers:



*Thank you!*

## HS in the News

For additional Health Sciences news, please visit:

<http://hscnews.unm.edu/>

### **News or corrections?**

Please contact [the Newsletter Team](#).

The University Of New Mexico Mailing Address:

One University of New Mexico

MSC 08 4635

Albuquerque, NM 87131